Blog

Companies that put the everyday investor first

Remedy's big sequel launch and a $200m VEON buyback, in our redesigned Curation Briefing.

Written by Curation

ShareXLinkedIn
Illustration for “Companies that put the everyday investor first”

Companies that put the everyday investor first

We have redesigned our newsletter. Every company in this email has chosen to talk directly to everyday investors, not just the big funds. Here is what they have been up to this week.

Deep dive 01: Remedy Entertainment (REMEDY FH)

Big sequel lands and receives strong reviews

CONTROL Resonant, the sequel to Remedy's multi-award-winning CONTROL, launched worldwide on Thursday 24 September on PlayStation 5, Xbox Series X|S and PC. Critics like it: it is sitting in the mid-80s on Metacritic across platforms (84 PS5, 83-85 PC) from dozens of reviews, on par with the original game's scores, and several outlets are already floating it as a game-of-the-year contender.

The launch also demonstrates Remedy's ongoing shift from 3rd party developer to IP owner. Remedy owns the whole Control franchise outright, having bought the rights back in 2024. Keeping the IP means shareholders benefit more for the long-term success of the game, and opens the door to other monetisation avenues such as TV or film rights. If Remedy can build successful games under its own IP umbrella, that could dramatically improve the value of the business.

~84 Metacritic (PS5) · 100% franchise owned · 15 Oct physical editions

Explore Remedy

Deep dive 02: VEON

VEON puts $200m behind its own shares

On Wednesday, VEON announced a new programme to buy back 3.9% of its outstanding shares (around $200m at current prices) upgrading the minimum $100m a year it had promised since 2025. By its own maths, that works out to roughly a 5.5% yield on the average share price over the past twelve months.

Every share bought back will be cancelled rather than held in reserve, so the remaining shares each represent a slightly bigger slice of the company. It follows an already-completed $100m buyback programme, signifying VEON's commitment to returning cash, the strong financial position of the company, and the management's view that the shares are undervalued.

$200m new buyback size · 3.9% of shares outstanding · 5.5% implied yield

Explore VEON

Also this week

Premier Uranium: A new chair as the US uranium push builds

Michael Harrison takes over as Chairman on Tuesday, following the recently announced strategic partnership with DISA Uranium. More.

Explainer: What is a share buyback, and why cancel the shares?

A buyback is a company using its own cash to purchase its own shares on the open market, the same way any investor would. Rather than holding those shares to reissue later, VEON is cancelling every one it buys. That shrinks the total number of shares in existence, so each share left in circulation owns a slightly larger piece of the same company. It is one of two main ways companies hand cash back to shareholders, the other being a dividend.

See VEON on CurationAI.

From the Collective

Bitcoin clears resistance, and the read-through for digital assets

Bitcoin pushed above $83,000 this week, clearing its prior high. The bigger structural story the Collective is watching is tokenisation: US regulators have opened a route to on-chain trading of listed shares, and if stablecoin-style settlement ends up carrying tokenised equities the way it already carries crypto, the infrastructure behind digital assets stands to benefit long before any single token does. CoinShares sits right in the middle of that infrastructure.

CoinShares: one of the world's largest digital-asset managers.

Sourced from: The Cut After Close, 21 September 2026 (internal Curation Collective note).

Best Content Shared This Week

🎥 Psychedelics Move Closer to Mainstream Medicine

Why Watch? Eli Lilly's $2.8bn acquisition of AtaiBeckley highlights how quickly psychedelic medicine is moving from experimental science toward Big Pharma. This explains how a synthetic compound derived from toad venom could overcome three of the biggest barriers to psychedelic treatment: long sessions, unpredictable dosing and difficult clinical trials, and why positive Phase 3 data could open the door to much broader adoption. Watch here.

🎧 Boom Supersonic: Disrupting Aircraft Engines

Why Listen? Boom's supersonic ambitions are becoming an engine and infrastructure story as much as an aircraft one. The discussion explores why bringing engine development in-house could challenge the traditional aerospace supply chain, while Boom's move into 42MW data-centre power systems creates a potential revenue stream before its airliner ever flies, with interesting read-throughs for Boeing, Rolls-Royce and United Airlines. Listen here.

THIS ARTICLE DOES NOT CONSTITUTE ANY FORM OF ADVICE OR RECOMMENDATION AND IS NOT INTENDED TO BE RELIED UPON IN MAKING ANY INVESTMENT DECISIONS. Curation is an information service provided by Curation Corporation. Liability Your investments are your responsibility. No liability whatsoever is accepted by Curation Corporation Limited or any Curation Corporation company of their respective directors, officers, employees or analysts for any loss, whether direct, indirect, special, incidental or consequential, arising whether directly or indirectly as a result of the recipient acting or not acting on any information in any Curation publication, including, without limitation, lost profits arising from the use of the Curation service or any of its publications. We have no liability for any loss of profit, loss of revenue, loss of business, business interruption, loss of opportunity or any indirect, special or consequential loss; any losses which arise from any event beyond our reasonable control; any losses which could not reasonably have been anticipated; or your inability to access and/or use the Curation service or the website. We do not exclude or limit in any way our liability to you where it would be unlawful to do so. Disclaimer Curation publications are provided for general information purposes only and should not be regarded as an offer, solicitation, invitation, inducement or recommendation relating to the subscription, purchase or sale of any security or other financial instrument or investment. This document does not constitute, and should not be interpreted as, investment advice. You must carry out your own independent research and obtain suitable professional advice before making any investment decision. The Curation publications do not take the specific needs, investment objectives and financial situation of any particular individual into consideration and we cannot state whether any investment mentioned is suitable for you. You should not base any investment decision solely on the basis of the information we publish or provide to you. Always be aware of market risks, never invest money you cannot afford to lose. All investments can go down as well as up. Investing in securities entails risks. Potential Conflicts of Interest Curation or its respective directors, officers, employees, contributors and clients may have or take positions in the securities, entities or investments mentioned in the Curation publications. Any of these circumstances could create, or be perceived as creating, conflicts of interest. Privacy and Registration All information received from you and your use of the Curation service and the website will be used by Curation Corporation Limited in accordance with our Privacy Policy. Please read this for details of how we may process your personal data. On registration for the Curation service, you must provide us with accurate, complete registration information and it is your responsibility to update and maintain changes to your information. Curation, a trading name of Curation Corporation Limited, is entitled to rely on any information you provide to us. Read our full T&Cs, disclaimers and privacy notice. Contact us at info@curationcorp.com , Curation Corporation Limited, 42-46 Princelet St, London, E1 5LP, UK Read our Disclaimers.

Stock ideas your AI can't see.

Powered by a $250bn AUM investor network. Ask about the companies you follow and get bull case, bear case, catalysts and risks, free to start.

Get started, it's free
Go to blog →